𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Structure–activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase

✍ Scribed by Bart Van't Riet; Lemont B. Kier; Howard L. Elford


Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
243 KB
Volume
69
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Mechanisms of action of peptide inhibito
✍ Ying Gao; Ossama B. Kashlan; Jaskiran Kaur; Chiheng Tan; Barry S. Cooperman 📂 Article 📅 2005 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 203 KB

Mammalian ribonucleotide reductase (mRR) is a chemotherapeutic target. The enzyme is composed of 2 subunits (mR1 and mR2) and is inhibited by Ac-FTLDADF (denoted P7), corresponding to the C-terminus of mR2, which competes with mR2 for binding to mR1. mRR has 2 physiologically important active forms,

ChemInform Abstract: Synthesis and Biolo
✍ Sebastian Liehr; Joseph Barbosa; Amos B. Smith III; Barry S. Cooperman 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 26 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Principal component regression analysis
✍ Peter P. Mager 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB 👁 1 views

## Abstract The principal component regression analysis is used when the predicting variables correlate significantly against the regressor variables and, when a collinearity and multicollinearity exist among regressor variables. The example adapted from enzymology shows that no loss of information

Inhibitors of vitamin D hydroxylases: St
✍ Inge Schuster; Helmut Egger; Peter Nussbaumer; Romano T. Kroemer 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

## Abstract Aiming at new drugs to efficiently treat diseases, in which either increased or decreased levels of active vitamin D are desirable, we have designed some 400 structurally different azole‐type inhibitors and examined their capacity to selectively block vitamin D metabolism by CYP24 or sy